Cardiovascular Systems (CSII) Announces FDA Approval for Diamondback 360 Coronary OAS Micro Crown


News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.


Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII) announced that the United States Food and Drug Administration (FDA) has approved the Diamondback 360® Coronary OAS Micro Crown system to facilitate stent delivery in patients with coronary artery disease (CAD) who are acceptable candidates for PTCA or stenting due to de novo, severely calcified coronary artery lesions.

The Diamondback 360® Coronary OAS Micro Crown retains the novel mechanism of action of the Diamondback 360® Coronary OAS Classic Crown. Both systems allow treatment of multiple vessel sizes with one device while providing continuous flow of blood during treatment, which is important for both acute and long-term success. The OAS Micro Crown is the only device incorporating a diamond-coated tip to immediately engage and pilot through tight, severely calcified lesions that would otherwise be difficult to access, while also treating up to 4mm vessels with the same device. The increased mass of the sanding crown allows for lower rotational speeds, while maintaining the same orbit diameter as the OAS Classic Crown.

“We are committed to continued advancement of CSI’s proven OAS technology focused on severe coronary arterial calcium, which is an underserved problem in vascular medicine,” said Scott Ward, Chairman, President and Chief Executive Officer of CSI. “Patients with severely calcified coronary lesions are some of the most difficult to treat, leading to worse clinical and economic outcomes. The ORBIT II and COAST studies demonstrated that orbital atherectomy technology is safe and effective in treating patients with severely calcified lesions.”

COAST was a Harmonization-By-Doing clinical study for the OAS Micro Crown conducted in both the United States and Japan under the regulations of both governments. COAST was led by U.S. National Principal Investigator, Gregg W….

Read the full article from the Source…

Back to Top